Daval International Ltd.

Daval International Ltd. (Daval) is a privately held biotechnology company that is engaged in research, development and commercialization of putative anti-inflammatory medications. The company focused heavily on its research and development operations and is currently developing aimspro and ceremben as its major products for human and veterinary therapeutic applications, respectively in phase II clinical trials. It develops aimspro for modulation of the Hypothalamo-Pituitary-Adrenal axis and for some anti-inflammatory applications and the US Government, through the department of health and human services, has designated AIMSPRO as an orphan-drug for the treatment of amyotrophic lateral sclerosis (ALS). Daval has secured its product portfolio with a broad portfolio of patents comprising of 16 granted patents and 7 patent applications across the world. The company is headquartered in East Sussex, the UK.

Street: 
4a Gildredge Road
City: 
East Sussex
Postcode: 
BN21 4RL
Federal State : 
United Kingdom
WebSite: 
www.davalinternational.com
Fax: 
44-845-6031190

Company Index Score

Current Index Score Historical Index Score
  • Daval International Ltd. currently scores 50 % in the index.
  • Daval International Ltd. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Daval International Ltd. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets